Selected article for: "acute sars respiratory syndrome coronavirus and lung significant"
Author: Hamidi, Seyed Hootan; Kadamboor Veethil, Sandhya; Hamidi, Seyedeh Harir
Title: Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective
  • Cord-id: j18gluth
  • Document date: 2021_4_21
    • ID: j18gluth
    Snippet: BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes pulmonary injury or multiple-organ injury by various pathological pathways. Transforming growth factor-beta (TGF-β) is a key factor that is released during SARS-CoV-2 infection. TGF-β, by internalization of the epithelial sodium channel (ENaC), suppresses the anti-oxidant system, downregulates the cystic fibrosis transmembrane conductance regulator (CFTR), and activates the plasminogen activator inhibitor 1 (PAI-1)
    Document: BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes pulmonary injury or multiple-organ injury by various pathological pathways. Transforming growth factor-beta (TGF-β) is a key factor that is released during SARS-CoV-2 infection. TGF-β, by internalization of the epithelial sodium channel (ENaC), suppresses the anti-oxidant system, downregulates the cystic fibrosis transmembrane conductance regulator (CFTR), and activates the plasminogen activator inhibitor 1 (PAI-1) and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kB). These changes cause inflammation and lung injury along with coagulopathy. Moreover, reactive oxygen species play a significant role in lung injury, which levels up during SARS-CoV-2 infection. DRUG SUGGESTION: Pirfenidone is an anti-fibrotic drug with an anti-oxidant activity that can prevent lung injury during SARS-CoV-2 infection by blocking the maturation process of transforming growth factor-beta (TGF-β) and enhancing the protective role of peroxisome proliferator-activated receptors (PPARs). Pirfenidone is a safe drug for patients with hypertension or diabetes and its side effect tolerated well. CONCLUSION: The drug as a theoretical perspective may be an effective and safe choice for suppressing the inflammatory response during COVID-19. The recommendation would be a combination of pirfenidone and N-acetylcysteine to achieve maximum benefit during SARS-CoV-2 treatment.

    Search related documents:
    Co phrase search for related documents
    • active domain and acute ards respiratory distress syndrome: 1
    • active form and acute ards respiratory distress syndrome: 1
    • active form and liver function: 1
    • active form and liver kidney: 1
    • activity exhibit and acute ards respiratory distress syndrome: 1, 2
    • activity exhibit and liver function: 1, 2
    • activity exhibit and liver kidney: 1
    • activity increase expression and acute lung injury: 1, 2
    • acute ards respiratory distress syndrome and adenine nadph dinucleotide phosphate: 1
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute lung injury and adenine nadph dinucleotide phosphate: 1
    • acute phase and liver function: 1, 2, 3, 4, 5, 6, 7
    • acute phase and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute pneumonia and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute pneumonia and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute pneumonia ards respiratory distress syndrome and liver kidney: 1, 2, 3